ABVX

Rating neutralAI Memo

Abivax

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Planned U.S. obefazimod NDA submission • 2026-12-31

Base target: $100 / p=45% prob

Biggest risk

At the $95.10 October 1 anchor, substantial regulatory and launch success is already needed to support an approximately $8.36 billion packet market capitalization. First-half 2026 R&D rose to €107.9 million, operating cash outflow reached €102.5 million, and commercial-preparation costs are expected to increase; the projected runway depends on current operating assumptions [#PR-EARNINGS-2026-09-21]. Company release

Invalidation

Break below $55 or thesis failure.

What would change my mind?

Phase 3 progress, the planned NDA and a company-projected cash runway into Q4 2029 support a path toward potential commercialization without near-term financing pressure [#PR-EARNINGS-2026-09-21]. Company release

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

$100

p=45%

Bull target

$135

p=25%

Bear target

$55

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Obefazimod data presentations at UEG Week
ENHANCE-CD Phase 2b induction results
Phase 3 progress, the planned NDA and a company-projected cash runway into Q4 2029 support a path toward potential commercialization without near-term financing pressure [#PR-EARNINGS-2026-09-21].

BearKey bullets

Abivax's expanded safety analyses are company interpretations; malignancy and other long-term risks may receive further regulatory scrutiny [#PR-ABIVAX-2026-06-29].
Company release
Crohn's-disease Phase 2b results remain a separate binary clinical risk; positive ulcerative-colitis data do not establish efficacy in Crohn's disease [#PR-EARNINGS-2026-09-21].

WatchKey bullets

Planned U.S.

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $100 (p=45%)

Target spread vs base: +35% / -45%

Scenario probabilities

Bull Target: $135 (p=25%)Base Target: $100 (p=45%)Bear Target: $55 (p=30%)

Commentary

Company-confirmed runway and filing plans are constructive, but the September 30 UEG announcement schedules presentations rather than reporting new results. The packet does not establish a reliable post-results price reaction, earnings surprise, analyst revision series, or measured social/options/short-interest signals; zero-valued sentiment fields are unavailable-data placeholders, not observations. The deterministic prior is neutral with high uncertainty (0.881) and low evidence-quality score (0.08). Half-year results UEG announcement

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Obefazimod data presentations at UEG Week
ENHANCE-CD Phase 2b induction results

Scenarios

Bull Target (Scenario probability)

$135 / p=25% prob

Base Target (Scenario probability)

$100 / p=45% prob

Bear Target (Scenario probability)

$55 / p=30% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Planned U.S. obefazimod NDA submission
Abivax plans to submit its ulcerative-colitis NDA by year-end 2026 and reported alignment with FDA on submission strategy and format. Submission is not approval; completeness, safety and CMC remain review risks [#PR-ABIVAX-2026-07-30] [#PR-EARNINGS-2026-09-21]. FDA-interaction release Half-year results
Prob 75.00% • Move 12.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Obefazimod data presentations at UEG Week
2026-10-20
Abivax scheduled seven presentations for October 17–20 covering Phase 3 ulcerative-colitis results, longer-term Phase 2 follow-up and preclinical work. The September 30 announcement is a presentation schedule, not a new clinical readout; incremental safety or subgroup detail will matter more than the number of abstracts [#PR-ABIVAX-2026-09-30]. Company release
Prob 90% • Move 3% • Priced-in 80%

Long-term Catalysts

Months to a year

ENHANCE-CD Phase 2b induction results
2027-06-30
The company expects topline Crohn's-disease induction results in mid-2027. A positive result could broaden obefazimod's opportunity, but efficacy and safety in this separate indication remain unproven [#PR-EARNINGS-2026-09-21]. Company release
Prob 55% • Move 18% • Priced-in 30%

Risks

Abivax's expanded safety analyses are company interpretations; malignancy and other long-term risks may receive further regulatory scrutiny [#PR-ABIVAX-2026-06-29]. Company release
Crohn's-disease Phase 2b results remain a separate binary clinical risk; positive ulcerative-colitis data do not establish efficacy in Crohn's disease [#PR-EARNINGS-2026-09-21]. Company release
FDA review could identify deficiencies in the obefazimod safety, efficacy or CMC package; the positive pre-NDA interaction does not imply approval [#PR-ABIVAX-2026-07-30]. Company release
Rising R&D, commercial-readiness spending and operating cash use could shorten the projected runway if costs exceed current assumptions [#PR-EARNINGS-2026-09-21]. Company release

Peers

Symbol	Summary
PCVX	Development-stage biotech of similar packet market capitalization, but its vaccine programs are not direct ulcerative-colitis comparators; market-cap similarity is not a valuation multiple.
PRAX	Development-stage biotech of similar packet market capitalization, but its neuroscience pipeline makes it a loose funding-and-clinical-risk comparator, not a direct obefazimod peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

PCVX

Development-stage biotech of similar packet market capitalization, but its vaccine programs are not direct ulcerative-colitis comparators; market-cap similarity is not a valuation multiple.

PRAX

Development-stage biotech of similar packet market capitalization, but its neuroscience pipeline makes it a loose funding-and-clinical-risk comparator, not a direct obefazimod peer.